Teva Pharmaceutical Industries Limited filed an 8-K with the U.S. Securities and Exchange Commission on September 16, 2026, disclosing the issuance of multiple tranches of senior notes totaling approximately $4.7 billion equivalent through three wholly owned subsidiaries.

Key Highlights

  • Five tranches issued: Two Euro-denominated and three USD-denominated series of senior notes were issued on September 16, 2026.
  • Euro Notes: Teva Finance II issued EUR 1,000,000,000 of 4.250% Senior Notes due 2033 and EUR 500,000,000 of 4.625% Senior Notes due 2036.
  • USD Notes: Teva Finance III issued $1,000,000,000 of 5.500% Senior Notes due 2034 and $1,000,000,000 of 5.750% Senior Notes due 2037; Teva Finance IV issued $1,200,000,000 of 5.250% Senior Notes due 2032.
  • Proceeds use: According to the filing, net proceeds are intended primarily to fund redemptions of certain existing notes, pay related fees and expenses, and, to the extent of remaining proceeds, for general corporate purposes including repayment of outstanding debt.
  • Guarantee structure: All Notes are senior unsecured obligations of the respective issuing subsidiaries and are guaranteed on a senior unsecured basis by Teva Pharmaceutical Industries Limited.
  • Trustee: The Bank of New York Mellon serves as trustee across all indentures governing the Notes.

Teva Finance Subsidiaries Price Multi-Tranche Debt Offering Across Euro and USD Markets

According to the filing, three wholly owned subsidiaries of Teva Pharmaceutical Industries Limited (NYSE:TEVA) completed separate but concurrent debt issuances on September 16, 2026. Teva Pharmaceutical Finance Netherlands II B.V. issued the two Euro-denominated tranches, Teva Pharmaceutical Finance Netherlands III B.V. issued two of the USD tranches, and Teva Pharmaceutical Finance Netherlands IV B.V. issued the third USD tranche. Each subsidiary acts as a distinct issuer under its own indenture, all guaranteed by the parent company.

The filing specifies distinct interest payment schedules for each series. Interest on the 2033 Euro Notes is payable annually on March 16, beginning March 16, 2027. Interest on the 2036 Euro Notes is payable annually on September 16, beginning September 16, 2027. The USD Notes pay interest semi-annually on January 16 and July 16 each year, beginning January 16, 2027, with maturities on January 16, 2032, January 16, 2034, and January 16, 2037, respectively. The filing also describes optional early redemption provisions for each series, with make-whole call structures and par call windows ranging from one to three months before maturity depending on the tranche.

The filing further discloses that the indentures include an obligation to offer to repurchase the notes at a price equal to 101% of principal under certain circumstances, though the filing as provided does not complete the description of that provision. The Euro Notes Base Indenture dates to March 14, 2018, with the current issuances made under the Sixth Supplemental Indenture for Teva Finance II and Teva Finance III, and the Second Supplemental Indenture for Teva Finance IV, which was established under a base indenture dated May 28, 2025.

What Was Disclosed

Teva disclosed the September 16, 2026 issuance of five series of senior unsecured notes across three subsidiaries, totaling EUR 1.5 billion and $3.2 billion, guaranteed by the parent, with proceeds intended primarily for redemptions of existing notes and related expenses.